166 related articles for article (PubMed ID: 19732414)
61. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer.
Kasper S; Sheppard PC; Yan Y; Pettigrew N; Borowsky AD; Prins GS; Dodd JG; Duckworth ML; Matusik RJ
Lab Invest; 1998 Jun; 78(6):i-xv. PubMed ID: 9645768
[TBL] [Abstract][Full Text] [Related]
62. PAK1 hyperactivation is sufficient for mammary gland tumor formation.
Wang RA; Zhang H; Balasenthil S; Medina D; Kumar R
Oncogene; 2006 May; 25(20):2931-6. PubMed ID: 16331248
[TBL] [Abstract][Full Text] [Related]
63. Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors.
Wang W; Wyckoff JB; Goswami S; Wang Y; Sidani M; Segall JE; Condeelis JS
Cancer Res; 2007 Apr; 67(8):3505-11. PubMed ID: 17440055
[TBL] [Abstract][Full Text] [Related]
64. Imaging Tumor Necrosis with Ferumoxytol.
Aghighi M; Golovko D; Ansari C; Marina NM; Pisani L; Kurlander L; Klenk C; Bhaumik S; Wendland M; Daldrup-Link HE
PLoS One; 2015; 10(11):e0142665. PubMed ID: 26569397
[TBL] [Abstract][Full Text] [Related]
65. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.
Liu R; Varghese S; Rabkin SD
Cancer Res; 2005 Feb; 65(4):1532-40. PubMed ID: 15735042
[TBL] [Abstract][Full Text] [Related]
66. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
67. Comparison of MRI features of different grades of DCIS and invasive carcinoma of the breast.
Van Goethem M; Schelfout K; Kersschot E; Colpaert C; Weyler J; Verslegers I; Biltjes I; De Schepper A; Parizel PM
JBR-BTR; 2005; 88(5):225-32. PubMed ID: 16302331
[TBL] [Abstract][Full Text] [Related]
68. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
Li M; Lewis B; Capuco AV; Laucirica R; Furth PA
Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684
[TBL] [Abstract][Full Text] [Related]
69. Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression.
Huh JI; Calvo A; Charles R; Green JE
Cancer Res; 2006 Apr; 66(7):3495-503. PubMed ID: 16585173
[TBL] [Abstract][Full Text] [Related]
70. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Coulson R; Liew SH; Connelly AA; Yee NS; Deb S; Kumar B; Vargas AC; O'Toole SA; Parslow AC; Poh A; Putoczki T; Morrow RJ; Alorro M; Lazarus KA; Yeap EFW; Walton KL; Harrison CA; Hannan NJ; George AJ; Clyne CD; Ernst M; Allen AM; Chand AL
Oncotarget; 2017 Mar; 8(12):18640-18656. PubMed ID: 28416734
[TBL] [Abstract][Full Text] [Related]
71. Ductal carcinoma in situ: is there a role for MRI?
Zuiani C; Francescutti GE; Londero V; Zunnui I; Bazzocchi M
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):89-95. PubMed ID: 12585661
[TBL] [Abstract][Full Text] [Related]
72. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
73. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression.
Hutchinson J; Jin J; Cardiff RD; Woodgett JR; Muller WJ
Mol Cell Biol; 2001 Mar; 21(6):2203-12. PubMed ID: 11238953
[TBL] [Abstract][Full Text] [Related]
74. Transgenic Polyoma middle-T mice model premalignant mammary disease.
Maglione JE; Moghanaki D; Young LJ; Manner CK; Ellies LG; Joseph SO; Nicholson B; Cardiff RD; MacLeod CL
Cancer Res; 2001 Nov; 61(22):8298-305. PubMed ID: 11719463
[TBL] [Abstract][Full Text] [Related]
75. Characterization of neuro-endocrine tumors in an athymic nude mouse model using dedicated synchronization strategies for T2-weigted MR imaging at 7T.
Baboi LM; Milot L; Lartizien C; Roche C; Scoazec JY; Pilleul F; Beuf O
Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():2879-82. PubMed ID: 18002596
[TBL] [Abstract][Full Text] [Related]
76. In situ and minimally invasive breast cancer: morphologic and kinetic features on contrast-enhanced MR imaging.
Viehweg P; Lampe D; Buchmann J; Heywang-Köbrunner SH
MAGMA; 2000 Dec; 11(3):129-37. PubMed ID: 11154954
[TBL] [Abstract][Full Text] [Related]
77. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice.
Sandgren EP; Schroeder JA; Qui TH; Palmiter RD; Brinster RL; Lee DC
Cancer Res; 1995 Sep; 55(17):3915-27. PubMed ID: 7641211
[TBL] [Abstract][Full Text] [Related]
78. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.
Moody SE; Sarkisian CJ; Hahn KT; Gunther EJ; Pickup S; Dugan KD; Innocent N; Cardiff RD; Schnall MD; Chodosh LA
Cancer Cell; 2002 Dec; 2(6):451-61. PubMed ID: 12498714
[TBL] [Abstract][Full Text] [Related]
79. Progression of prostate cancer from a subset of p63-positive basal epithelial cells in FG/Tag transgenic mice.
Reiner T; de Las Pozas A; Parrondo R; Perez-Stable C
Mol Cancer Res; 2007 Nov; 5(11):1171-9. PubMed ID: 17982114
[TBL] [Abstract][Full Text] [Related]
80. Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells.
Galiè M; Sorrentino C; Montani M; Micossi L; Di Carlo E; D'Antuono T; Calderan L; Marzola P; Benati D; Merigo F; Orlando F; Smorlesi A; Marchini C; Amici A; Sbarbati A
Carcinogenesis; 2005 Nov; 26(11):1868-78. PubMed ID: 15975963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
